Categories Earnings, Health Care

Arbutus Biopharma (ABUS): FY19 Earnings Snapshot

— Arbutus Biopharma Corporation (NASDAQ:ABUS) reported a net loss of $164.9 million or $2.89 per share for fiscal 2019, compared to a loss of $67.2 million or $1.21 per share last year.

— Total revenues edged up to $6.01 million from $5.9 million in 2018

— Research and development expenses were almost unchanged year-over-year at $57.6 million in fiscal 2019

— Achieved progress in a focused discovery effort on follow-on compounds for the current HBV pipeline

— On track to advance a next-generation oral HBV specific RNA-destabilizer with chemical scaffolds distinct from AB-452 through lead optimization

— Ended 2019 with $90.8 million in cash, cash equivalents and short-term investments

— Expects to utilize between $54 to $58 million of cash and investments to fund operations in 2020

We’re on Apple News! Follow us to receive the latest stock market, earnings and financial news at your fingertips

Most Popular

Earnings Preview: What to look for when Broadcom (AVGO) reports Q1 results

Broadcom, Inc. (NASDAQ: AVGO) will be releasing its first-quarter results next week. Over the years, the company constantly broadened its portfolio beyond semiconductors to areas like enterprise software solutions, a

Here’s a look at Lowe’s (LOW) expectations for the near term and ahead

Shares of Lowe’s Companies, Inc. (NYSE: LOW) were up over 1% on Friday. The stock has gained 19% over the past three months. The home improvement retailer saw sales and

TJX Companies (TJX) Q4 2024 profit jumps on strong revenue growth

The TJX Companies, Inc. (NYSE: TJX) has reported a double-digit increase in net income for the fourth quarter of 2024 when the fashion retailer's net sales grew 13%. Fourth-quarter sales

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top